Skip to search formSkip to main contentSkip to account menu

CER-001

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Apolipoprotein A-IPhospholipidsRecombinant Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Remodeling And Catabolism Of Cer-001 In Absence Of Lcat Enzyme
Review
2017
Review
2017
Dietary Strategies and Novel Pharmaceutical Approaches Targeting Serum ApoA-I Metabolism: A Systematic Overview
The incidence of CHD is still increasing, which underscores the need for new preventive and therapeutic approaches to decrease… 
2016
2016
A phase III multicentre, double-blind, placebo-controlled study (TANGO) to evaluate CER-001 on carotid atherosclerosis (vessel wall area) in patients with familial primary hypoalphalipoproteinaemia
2016
2016
Clinical tolerability and safety profile of CER-001, a novel bio-engineered pre-β HDL-mimetic, across the clinical development programme
2015
2015
It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
Clinical intervention studies have provided clear evidence that low‐density lipoproteins are causally involved in the development… 
Review
2015
Review
2015
Non-clinical development of CER-001
Cardiovascular disease remains the most pressing healthcare issue for the developed world and is becoming so for developing… 
2015
2015
Abstract 12156: Greater Regression of Coronary Atherosclerosis With the Pre-Beta High-Density Lipoprotein Mimetic CER-001 in Patients With More Extensive Plaque Burden
Introduction: Infusing high-density lipoprotein (HDL) has been shown to promote plaque regression in patients with acute coronary… 
2014
2014
Effect of open-label infusion of an apolipoprotein A-I-containing particle ( CER-001 ) on reverse cholesterol transport and artery wall thickness in patients with familial hypo-alphalipoproteinemia
  • 2014
  • Corpus ID: 6058876
Background Reverse cholesterol transport (RCT) contributes to the anti-atherogenic effects of High-density lipoprotein (HDL… 
2014
2014
Trying to harness the potential of HDL: wishful thinking or sound strategy?
This editorial refers to ‘Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients… 
2011
2011
Abstract 15525: CER-001, a Synthetic HDL-Mimetic, Safely Mobilizes Cholesterol in Healthy Dyslipidemic Volunteers
Background: CER-001 is a synthetic HDL, comprised of recombinant human ApoA-I complexed with phospholipids and designed to mimic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)